Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients

European Journal of Haematology

Volumn 90, Issue 3, 2013, Pages 237-244

  Shoji, Shigeichi ^a   Inaba, Masaaki ^b   Tomosugi, Naohisa ^c   Okuno, Senji ^a   Ichii, Mitsuru ^b   Yamakawa, Tomoyuki ^a   Kurihara, Satoshi ^d  

^a OSAKA CITY UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d Saitama Tsukinomori Clinic   (Japan)

Author keywords

Anemia; Darbepoetin; Erythropoietin; Ferritin; Hemodialysis; Hepcidin 25; Iron

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ANEMIA; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HUMAN; IRON BLOOD LEVEL; IRON KINETICS; IRON METABOLISM; IRON STORAGE; MALE; PRIORITY JOURNAL; TRANSFERRIN BLOOD LEVEL;

AGED; ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; AREA UNDER CURVE; CROSS-OVER STUDIES; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS;

EID: 84873975501     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12067     Document Type: Article

References (32)

1. Chung S, Song HC, Shin SJ, Ihm SH, Park CS, Kim HY, Yang CW, Kim YS, Choi EJ, Kim YK. Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis. Hemodial Int 2012;16:181-7.
2. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
3. Locatelli F, Aljama P, Bàràny P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47.
4. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(Suppl 3):S11-45.
5. Kuragano T, Itoh K, Shimonaka Y, et al. Hepcidin as well as TNF-α are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011;26:2663-7.
6. Kalantar-Zadeh K, Regidor DL, Mcallister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070-80.
7. Hasuike Y, Nonoguchi H, Tokuyama M, Ohue M, Nagai T, Yahiro M, Nanami M, Otaki Y, Nakanishi T. Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Clin Exp Nephrol 2010;14:349-55.
8. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(Suppl 1):3-10.
9. Scott DS. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendation from clinical studies. Pharmacotherapy 2002;22:160S-5S.
10. Murano N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007;21:4033-8.
11. Maekawa K, Shoji T, Emoto M, Okuno S, Yamakawa T, Ishimura E, Inaba M, Nishizawa Y. Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrol Dial Transplant 2008;23:2329-36.
12. Uehata T, Tomosugi N, Shoji T, et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant 2012;27:1076-83.
13. Gabbe EE, Heinrich HC, Icagić F. Proposal for the standardization of the serum unsaturated iron binding capacity assay, and results in groups of subjects with normal iron stores and with prelatent, latent, and manifest iron deficiency. Clin Chim Acta 1982;119:51-63.
14. Nakanishi T, Kuragano T, Nanami M, Otaki Y, Nonoguchi H, Hasuike Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol 2010;32:439-46.
15. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996;1275:161-203.
16. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 2007;18:394-400.
17. Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012;89:87-93.
18. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
19. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006;108:3730-5.
20. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB. Hepcidin - a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-6.
21. van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, Braam B, Gaillard CA. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 2010;12:943-50.
22. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loréal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811-19.
23. Mazur A, Feillet-Coudray C, Romier B, Bayle D, Gueux E, Ruivard M, Coudray C, Rayssiguier Y. Dietary iron regulates hepatic hepcidin 1 and 2 mRNAs in mice. Metabolism 2003;52:1229-31.
24. Yahiro M, Kuragano T, Kida A, Kitamura R, Furuta M, Hasuike Y, Otaki Y, Nonoguchi H, Nakanishi T. The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients. Clin Exp Nephrol 2012;16:448-55.
25. Ford BA, Coyne DW, Eby CS, Scott MG. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int 2009;75:104-10.
26. Tsubakihara Y, Nishi S, Akiba T, et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010;14:240-75.
27. Sengoelge G, Sunder-Plassmann G, Hörl WH. Potential risk for infection and atherosclerosis due to iron therapy. J Ren Nutr 2005;15:105-10.
28. Kletzmayr J, Hörl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 2002;17(Suppl 2):25-9.
29. Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2001;37:564-72.
30. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, Frederic PM, Daemen MJ, van Engelshoven JM. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003;107:2453-8.
31. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end stage renal disease. Circulation 2002;106:2212-17.
32. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.